Rivastigmine Tartrate NDC 62756-146

NDC codes

FDA NDC Directory

Product NDC (as listed)62756-146Labeler and product segments. Claims need a package NDC.

Product NDC at billing width62756-0146Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
62756-146-13	62756014613	500 CAPSULE in 1 BOTTLE (62756-146-13)Marketed from Jul 1, 2010
62756-146-61	62756014661	100 BLISTER PACK in 1 BOX, UNIT-DOSE (62756-146-61) / 1 CAPSULE in 1 BLISTER PACKMarketed from Jul 1, 2010
62756-146-86	62756014686	60 CAPSULE in 1 BOTTLE (62756-146-86)Marketed from Jul 1, 2010

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Rivastigmine Tartrate
Generic name (nonproprietary): rivastigmine tartrate
Active ingredients: Rivastigmine tartrate — 3 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Sun Pharmaceutical Industries, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 077131
Marketing start: Jul 1, 2010
Listing expires: Dec 31, 2026
Other FDA classes: Cholinesterase Inhibitors (Mechanism)
Identifiers: Product ID 62756-146_a905f5ce-ae1b-4511-acd3-62883a3e3546SPL ID a905f5ce-ae1b-4511-acd3-62883a3e3546SPL set ID bac9ca81-db70-41aa-82af-6c5bb8496846RxCUI 312835, 312836, 314214, 314215UNII 9IY2357JPEUPC 0362756145863, 0362756147867, 0362756146860, 0362756148864
Pharmacologic class: Cholinesterase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N462756014613 followed by a unit qualifier and the quantity

Package 62756-0146-13. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 31, 2019.

Indications (excerpt from the label)

Rivastigmine tartrate is an acetylcholinesterase inhibitor indicated for treatment of: Mild-to-moderate dementia of the Alzheimer’s type (AD) ( 1.1 ) Mild-to- moderate dementia associated with Parkinson’s disease (PD) ( 1.2 ) 1.1 Alzheimer's Disease Rivastigmine tartrate capsules are indicated for the treatment of mild-to-moderate dementia of the Alzheimer's type (AD). 1.2 Parkinson's Disease Dementia Rivastigmine tartrate capsules are indicated for the treatment of mild-to-moderate dementia associated with Parkinson’s disease (PD).

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 077131

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 077131
Product	Strength	Form · route	Labeler	Product NDC
Rivastigmine Tartrate	Rivastigmine tartrate 6 mg/1	CapsuleOral	Sun Pharmaceutical Industries, Inc.	62756-148
Rivastigmine Tartrate	Rivastigmine tartrate 1.5 mg/1	CapsuleOral	Sun Pharmaceutical Industries, Inc.	62756-145
Rivastigmine Tartrate	Rivastigmine tartrate 4.5 mg/1	CapsuleOral	Sun Pharmaceutical Industries, Inc.	62756-147